CYAD News and Press, Celyad SA From 05/05/22

MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext & Nasdaq: CYAD), please note that in the First Quarter 2022 Financial Review section, the figures for cash and cash equivalents an...

Enrollment continues in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM) Dialogue continues with regulatory agencies concerning CYAD-101-002 Phase 1b trial, which remains on ...

Celyad Oncology SA (CYAD) Q4 2021 Earnings Conference Call March 25, 2022 08:00 ET CompanyParticipants Daniel Ferry - LifeSci Advisors Filippo Petti - Chief Executive Officer Charles Morris - Chief Medical Officer David Gilham - Chief Scientific Officer Conference Call Participants Raju Prasa...

Highlights Phase 1 IMMUNICY-1 trial demonstrated encouraging data to date for CYAD-211 including a good tolerability profile and evidence of clinical activity in relapsed/refractory multiple myeloma (r/r MM) patients Investigation ongoing of findings in CYAD-101-002 Phas...

Celyad Oncology press release (NASDAQ:CYAD): FY GAAP EPS of -€1.70. Cash position of €30.0 million ($34.0 million) as of December 31, 2021 For further details see: Celyad Oncology GAAP EPS of -€1.70

MONT-SAINT-GUIBERT, Belgium, March 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Compan...

Gainers: Sunshine Biopharma (NASDAQ:SBFM) +159%. Cano Health (NYSE:CANO) +34%. Celyad Oncology (NASDAQ:CYAD) +24%. Mainz Biomed (NASDAQ:MYNZ) +21%. Bright Health Group (NYSE:BHG) +17%. Losers: Ontrak (NASDAQ:OTRK) -20%. Invacare (NYSE:IVC) -19%. Na...

Sunshine Biopharma (NASDAQ:SBFM) +201% on rising volume. American Rebel Holdings (NASDAQ:AREB) +28%. Bumble (NASDAQ:BMBL) +23% on Q4 results. Ecoark Holdings (NASDAQ:ZEST) +22% announces successful drilling of Louisiana oil well. Imperial Petroleum (NASDAQ:IMPP) ...

The U.S. Food and Drug Administration placed a clinical hold on Celyad Oncology's (NASDAQ:CYAD) phase 1b trial, dubbed CYAD-101-002 (KEYNOTE-B79), due to insufficient information to assess risk to study patients. On Feb. 28, Celyad said it had voluntarily paused the phase 1b st...

MONT-SAINT-GUIBERT, Belgium, March 02, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, t...